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Effect of periodontal treatment on receptor activator of NF-κB
ligand and osteoprotegerin levels and relative ratio in gingival
crevicular fluid
Abstract
Aim: Receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG) have an established role
in the pathogenesis of periodontitis, which is characterized by an increased RANKL/OPG ratio. The
present study aims to investigate changes of RANKL, OPG and their relative ratio in gingival crevicular
fluid (GCF) of periodontitis patients after non-surgical periodontal treatment.
Materials and Methods: GCF was obtained from chronic periodontitis (n=14), generalized aggressive
periodontitis (G-AgP; n=13) patients at baseline. The patients received scaling and root planing and
were recalled after 2, 3 and 4 months for follow-up clinical examination and sampling. The total
amounts and concentrations of RANKL and OPG in GCF were measured by enzyme-linked
immunosorbent assay, and their relative ratio was calculated.
Results: The RANKL/OPG ratio remained unchanged and did not correlate with clinical parameters
throughout the monitoring period, despite the improved clinical outcome. This trend was similar in both
chronic and G-AgP.
Conclusions: Although the RANKL/OPG ratio has a potential diagnostic value for untreated
periodontitis, it may not be a suitable predictor of clinically successful treatment outcome. As
conventional therapy does not negatively modulate this ratio, the host could still be susceptible to further
periodontal tissue destruction, warranting the consideration of adjunctive treatments.
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Abstract
Aim: Receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG) have
an established role in the pathogenesis of periodontitis, which is characterized by an
increased RANKL/OPG ratio. The present study aims to investigate changes of
RANKL, OPG and their relative ratio in gingival crevicular fluid (GCF) of
periodontitis patients after non-surgical periodontal treatment.
Materials and Methods: GCF was obtained from chronic periodontitis (n5 14),
generalized aggressive periodontitis (G-AgP; n5 13) patients at baseline. The patients
received scaling and root planing and were recalled after 2, 3 and 4 months for follow-
up clinical examination and sampling. The total amounts and concentrations of
RANKL and OPG in GCF were measured by enzyme-linked immunosorbent assay,
and their relative ratio was calculated.
Results: The RANKL/OPG ratio remained unchanged and did not correlate with
clinical parameters throughout the monitoring period, despite the improved clinical
outcome. This trend was similar in both chronic and G-AgP.
Conclusions: Although the RANKL/OPG ratio has a potential diagnostic value for
untreated periodontitis, it may not be a suitable predictor of clinically successful
treatment outcome. As conventional therapy does not negatively modulate this ratio,
the host could still be susceptible to further periodontal tissue destruction, warranting
the consideration of adjunctive treatments.
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Alveolar bone loss is a key clinical
feature of periodontitis. On the molecu-
lar level, bone resorption is regulated by
the interplay of receptor activator of NF-
kB ligand (RANKL) and osteoproteger-
in (OPG), two molecules belonging to
the tumour necrosis factor ligand and
receptor families, respectively (Teitel-
baum & Ross 2003). On the cellular
level, RANKL is expressed predomi-
nantly as a membrane-bound or secreted
ligand by osteoblasts, fibroblasts and
activated T and B cells (Liu et al.
2010). By activating its cognate RANK
receptor on osteoclast precursors (cells
of the monocyte/macrophage lineage), it
triggers their fusion and differentiation
into multi-nucleated osteoclasts, which
will resorb bone (Lacey et al. 1998). On
the contrary, OPG is a soluble inhibitor
that binds to RANKL, thus preventing
osteoclast differentiation and bone resor-
ption (Simonet et al. 1997). RANKL and
OPG production is regulated by several
systemic and local stimuli, including
hormones, inflammatory mediators and
bacterial products (Lerner 2006).
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There is now a wide body of convin-
cing evidence for the role of the
RANKL–OPG system in human perio-
dontitis (Taubman et al. 2007), that
could potentially be exploited for diag-
nostic or therapeutic purposes (Bartold
et al. 2010). Recent clinical studies have
confirmed that both RANKL and OPG
can be detected in human gingival cre-
vicular fluid (GCF). These studies col-
lectively indicate that RANKL levels
are increased, whereas OPG levels are
decreased in GCF from periodontitis-
affected sites (Mogi et al. 2004, Vernal
et al. 2004, Lu et al. 2006, Bostanci et
al. 2007, Tang et al. 2009). An increase
in the relative RANKL/OPG ratio is
considered indicative of the occurrence
of periodontitis (Bostanci et al. 2007).
These cross-sectional studies have vali-
dated the RANKL–OPG system as a
potential molecular diagnostic marker
for periodontitis. However, there is at
present only little information on the
potential quantitative changes in this
system in response to periodontal ther-
apy. Therefore, the aim of this study was
to investigate the effect of non-surgical
periodontal treatment on RANKL, OPG
and RANKL/OPG ratio levels in GCF of
patients with periodontitis, over a period
of 4 months.
Materials and Methods
Study population and clinical examination
A total of 27 patients were included in
this study. Pre-screening examination
was conducted to evaluate patient elig-
ibility for inclusion in the study. Patients
eligible for the study returned to the
clinic at screening visit for clinical
measurements, 1 week after pre-screen-
ing. All subjects were recruited from the
Department of Periodontology (School
of Dentistry, Ege University, I˙zmir,
Turkey). The study was approved by
the Ethics Committee of the Medical
Faculty of Ege University and was con-
ducted according to the guidelines of the
World Medical Association Declaration
of Helsinki. Written and informed con-
sent was obtained from each patient
before enrolment in the study. Complete
medical and dental histories were taken
from all patients. Systemic exclusion
criteria were smoking, cardiovascular
and respiratory diseases, diabetes melli-
tus, hepatitis or HIV infection, immuno-
suppressive chemotherapy and current
pregnancy or lactation. None of the
patients had taken medication such as
antibiotics or contraceptives that could
affect their periodontal status for at least
3 months before the study. The selection
of the patients was made according to
the clinical and radiographic criteria
proposed by the 1999 International
World Workshop for a Classification of
Periodontal Disease and Conditions
(Armitage 1999). The periodontal status
of each patient was assessed by a single
calibrated examiner having experience
in clinical trials (B. S.). The intra-exam-
iner reproducibility for probing pocket
depth (PPD) measurements was assessed
and the inter-class correlation coefficient
was 0.985 (95% confidence interval:
0.968–0.993). To determine the clinical
periodontal status, all subjects had a
clinical periodontal examination includ-
ing the measurement of PPD and clinical
attachment level (CAL) at six sites
around each tooth with a manual probe
(Williams probe). The full-mouth papil-
la bleeding index (PBI) and plaque
index (PI) were also recorded. The
patients were classified in two groups
based on diagnosis: (a) a generalized
aggressive periodontitis (G-AgP) group
(n5 13, eight females and five males)
with mean age 28.8  5.7 years
(between 18 and 36 years), demonstrat-
ing a generalized pattern of severe perio-
dontal destruction and CALX4mm on
eight or more teeth; at least three of
those were other than central incisors or
first molars, which was not consistent
with patients’ age, amount of plaque
accumulation or local contributing fac-
tors, and (b) a chronic periodontitis (CP)
group (n5 14, six females and eight
males) with mean age 44.7  5.0 years
(between 35 and 52 years), exhibiting at
least four sites with a PPDX6mm and
CALX4mm at the same site.
Periodontal treatment protocol
After the pre-screening and screening
visits, the patients received non-surgical
therapy starting at baseline with full-
mouth supragingival scaling, followed
by four weekly sessions of quadrant
root planing under local anaesthesia up
to 1 h until they were free of all deposits
as determined by visual or tactile exam-
ination. Oral hygiene instructions
including brushing, flossing and inter-
dental brushing were given at baseline
and reinforced at each recall session.
The recall visits occurred at 2, 3 and 4
months after completion of the treatment.
These were performed by the same
examiner and consisted of GCF sam-
pling, clinical measurements and reinfor-
cement of oral hygiene procedures.
Collection of GCF
At baseline and each follow-up time-
point, GCF samples were collected from
the mesiobuccal aspect of a single-
rooted tooth exhibiting PPD of 5–
8mm. The selected sites were cleared
of supragingival plaque, isolated with
cotton rolls and dried with a gentle
stream of air to prevent saliva contam-
ination. A sterile Periopaper strip (Pro-
Flow Inc. Amityville, NY, USA) was
gently inserted into the periodontal
pocket until mild resistance was felt
and left in place for 30 s. Mechanical
irritation was avoided and strips con-
taminated with blood were discarded.
The GCF sample volume was mea-
sured with a calibrated Periotron 8000
(Proflow Inc.) and then the readings
were converted to an actual volume
(ml) by reference to the standard curve.
Upon collection, the samples were
immediately stored at  801C before
lyophilization, which was performed
by freeze-drying under vacuum. For
laboratory analysis, 200ml of phosphate
buffered saline (pH 7.2) was used to re-
elute the samples. The tubes were sha-
ken gently for 1min. and then centri-
fuged at 2000 g for 15min. at 41C,
before being processed on the enzyme-
linked immunosorbent assay (ELISA)
plate.
Quantification of RANKL and OPG
concentrations in GCF
The total amount of RANKL and OPG
in the GCF samples was determined by
human-specific ELISA in accordance
with the manufacturer’s instructions
(total sRANKL ELISA kit: Immundiag-
nostik AG, Bensheim, Germany, and
Osteoprotegerin ELISA kit: Biomedica,
Vienna, Austria). These assays measure
the total levels of RANKL or OPG
present in the GCF, including the
unbound forms, as well as the
RANKL–OPG complex. Calculation of
the RANKL and OPG concentration in
each GCF sample was performed by
dividing the total amount of RANKL
or OPG by the volume of GCF [RANKL
or OPG concentration (pg/ml)5 total
RANKL or OPG (pg)/GCF volume (ml)].
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Statistical analysis
Statistical analysis was performed using
the repeated measures analysis of var-
iance, and the Bonferroni post hoc test
to compare differences between groups.
In order to investigate the correlations
between RANKL, OPG and RANKL/
OPG ratio levels in GCF and clinical
parameters, Spearman’s rank correlation
analysis was used. Differences were
considered statistically significant at
po0.01.
Results
Clinical findings of at baseline and after
treatment
The full-mouth and site-specific clinical
data for the CP and G-AgP groups are
shown in Table 1. After treatment, both
CP and G-AgP groups exhibited signi-
ficant improvements of all clinical
parameters measures, at all follow-up
time-points (2, 3, 4 months), compared
with baseline.
Changes of RANKL levels after treatment
In the CP group, when the total amount
of RANKL was considered, there were
no changes over time after treatment
(Fig. 1a). However, the concentration
of RANKL was increased from 433 
269 pg/ml at baseline, to 1212  862 pg/
ml after 2 months, 931  582 pg/ml after
3 months and 829  412 pg/ml after 4
months (Fig. 1b). This increase proved
to be significant (po0.01) only at 2
months post-treatment. In the G-AgP
group, the total amount of RANKL
was not altered up to 3 months post-
treatment, but this was significantly
(po0.01) increased after 4 months
(Fig. 1a). Accordingly, the concentration
of RANKL was increased from 468 
580 pg/ml at baseline, to 924  434 pg/
ml after 2 months, 975  653 pg/ml after
3 months and 1313  620 pg/ml after 4
months, but only the latest proved to be
statistically significant (po0.001) (Fig.
1b), similar to the total amount of
RANKL. When RANKL levels were
compared between CP and G-AgP groups
at the various time-points, there were no
statistically significant differences.
Changes of OPG levels after treatment
In the CP group, neither the total
amounts (Fig. 2a) nor the concentration
levels (Fig. 2b) of OPG in GCF changed
significantly over the post-treatment
period, compared with baseline levels.
In the case of G-AgP, the total amount
of OPG in GCF did not change over the
4-month period after treatment (Fig. 2a).
However, the concentration of OPG was
increased from 71  74 pg/ml at base-
line, to 147  62 pg/ml after 2 months,
148  91pg/ml after 3 months and 207 
105 pg/ml after 4 months (Fig. 2b). The
latest increase (4 months), proved to be
statistically significant, as in the case of
RANKL concentration. Interestingly,
OPG concentration levels in the CP
group proved to be significantly
(po0.01) higher than the G-AgP group
at 4 months post-treatment (Fig. 2b).
Table 1. Clinical parameters before and after treatment (mean  standard deviation)
Full-mouth PPD (mm) CAL (mm) BOP (%) PI (%)
A. Chronic periodontitis (n5 14 subjects)
Baseline 3.82  0.56 5.32  1.00 65.6  17.8 88.4  20.7
2 months 2.38  0.33n 3.97  0.64n 18.5  7.8n 34.8  11.7n
3 months 2.33  0.28n 3.87  0.62n 17.7  8.0n 29.6  7.5n
4 months 2.15  0.24n 3.79  0.62n 15.3  6.3n 26.5  3.5n
Site specific PPD (mm) CAL (mm) PBI PI GCF (ml)
Baseline 5.98  1.14 7.14  1.83 2.0  1.8 2.8  0.9 0.31  0.22
2 months 2.50  0.51n 4.21  1.18n 0.2  0.4n 0.8  0.7n 0.14  0.11n
3 months 2.28  0.46n 3.92  1.07n 0.2  0.4n 0.6  0.6 0.15  0.07n
4 months 2.28  0.46n 4.28  1.13n 0.2  0.4n 0.5  0.6 0.10  0.06n
Full-mouth PPD (mm) CAL (mm) BOP (%) PI (%)
B. Generalized aggressive periodontitis (n5 13 subjects)
Baseline 4.28  0.73 5.15  0.67 80.3  17.2 93.8  8.7
2 months 2.45  0.25n 3.57  0.57n 22.9  7.4n 35.8  13.5n
3 months 2.39  0.26n 3.46  0.64n 24.3  13.8n 36.6  12.4n
4 months 2.21  0.20n 3.39  0.63n 21.7  9.2n 28.0  4.9n
Site specific PPD (mm) CAL (mm) PBI PI GCF (ml)
Baseline 7.30  1.37 7.92  1.44 2.3  0.8 2.5  1.0 0.40  0.35
2 months 3.23  0.92n 4.76  0.92n 0.4  0.6n 0.7  1.0n 0.12  0.05n
3 months 3.07  0.95n 4.53  1.26n 0.4  0.6n 0.6  0.6n 0.13  0.08n
4 months 2.84  0.80n 4.30  1.03n 0.3  0.5n 0.3  0.4n 0.10  0.06n
nSignificant difference from baseline (po0.001).
BOP, bleeding on probing; CAL, clinical attachment levels; GCF, gingival crevicular fluid volume; PBI, papilla bleeding index; PI, plaque index; PPD,
probing pocket depth.
430 Bostanci et al.
r 2011 John Wiley & Sons A/S
Changes in the RANKL/OPG ratio levels
after treatment
The relative RANKL/OPG ratio was
also calculated, based on the previously
obtained individual RANKL and OPG
total amounts, for both CP and G-AgP
groups. Interestingly, this ratio main-
tained unchanged from baseline and
throughout the post-treatment follow-
up period, in both CP and G-AgP groups
(Fig. 3). In addition, there were no
statistically significant differences bet-
ween CP and G-AgP groups at any of
the time-points.
Correlation of RANKL and OPG and
relative ratio with clinical parameters
The correlations of clinical parameters
with RANKL and OPG total amounts as
well as their relative ratio were investi-
gated by Spearman’s rank correlation
analysis (Table 2). The total amounts
were chosen over the concentrations for
the correlation analyses, in order to
eliminate the effect of GCF volume. In
the CP group, RANKL total amount was
negatively correlated with CAL,
whereas in the G-AgP group this was
negatively correlated with PBI.
Discussion
The RANKL–OPG system has an
important role in the pathogenesis of
periodontal disease. An increased
RANKL/OPG ratio is considered indi-
cative of the occurrence of untreated
periodontitis and it is suggested that it
could potentially serve as a molecular
diagnostic marker for the disease (Mogi
et al. 2004, Bostanci et al. 2007, Taub-
man et al. 2007). The present study was
undertaken with the aim to monitor
quantitative changes of the RANKL–
OPG system in GCF, in response to
non-surgical periodontal treatment,
over a period of 4 months.
The data indicate that periodontal
treatment does not affect RANKL or
OPG total amounts in CP patients.
Hence, conventional therapy alone can-
not modify the overall capacity of the
tissue to produce these factors. When
their concentration in GCF was consid-
ered, there was a transient increase of
RANKL and OPG levels at 2 months
post-treatment, which proved to be sta-
tistically significant in the case of
Fig. 1. Receptor activator of NF-kB ligand
(RANKL) total amounts (a) and concentra-
tions (b) in gingival crevicular fluid from
chronic periodontitis (CP; n5 14) and gen-
eralized aggressive periodontitis (G-AgP;
n5 13) patients, at baseline, 2, 3 and 4
months after treatment. The bars represent
the mean  standard error of mean in each
group and time-point. The asterisks indicate
statistically significant differences between
groups (npo0.01, nnpo0.001).
Fig. 2. Osteoprotegerin (OPG) total amo-
unts (a) and concentrations (b) in gingival
crevicular fluid from chronic periodontitis
(CP; n5 14) and generalized aggressive
periodontitis (G-AgP; n5 13) patients, at
baseline, 2, 3 and 4 months after treatment.
The bars represent the mean  standard
error of mean in each group and time-point.
The asterisks indicate statistically significant
differences between groups (npo0.01,
nnpo0.001).
Fig. 3. Receptor activator of NF-kB ligand/
osteoprotegerin (RANKL/OPG) ratio in gin-
gival crevicular fluid from chronic perio-
dontitis (CP; n5 14) and generalized
aggressive periodontitis (G-AgP; n5 13)
patients, at baseline, 2, 3 and 4 months after
treatment. The bars represent the mean
standard error of mean in each group and
time-point. No statistically significant differ-
ences were detected between patient groups
or time-points.
Table 2. Correlations between clinical para-
meters and total amounts of RANKL, OPG
and relative RANKL/OPG ratio
Clinical
parameters
RANKL OPG RANKL/
OPG
A. Chronic periodontitis
PPD 0.004  0.007 0.061
CAL  0.306n 0.181  0.262
PBI  0.041  0.228 0.110
PI  0.092  0.119 0.003
B. Generalized aggressive periodontitis
PPD  0.233  0.001  0.202
CAL  0.130  0.073  0.132
PBI  0.408n 0.038  0.363n
PI  0.195  0.098  0.071
The r value is provided.
Spearman’s rank correlation analysis was used.
npo0.01.
CAL, clinical attachment loss; OPG, osteopro-
tegerin; PI, plaque index; PBI, papilla bleeding
index; PPD, probing pocket depth; RANKL;
receptor activator of NF-kB ligand.
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RANKL. This is likely a result of the
reduced local inflammation, and subse-
quently of the lower GCF sampling
volume. Increased RANKL and OPG
GCF concentrations after periodontal
treatment have been reported previously
in a cohort of patients with diabetes
mellitus (Santos et al. 2010). Moreover,
another study reported no changes in
RANKL, but a decrease in OPG GCF
levels, 4 weeks after initial periodontal
treatment (Buduneli et al. 2009). In the
present study, the RANKL/OPG ratio
also remained unchanged despite the
improved clinical treatment outcomes.
A slight increase of the RANKL/OPG
expression ratio after non-surgical
periodontal treatment has been reported
previously in CP patients (Dereka et al.
2010). Hence, collectively from the pre-
sent and previous studies on CP (Budu-
neli et al. 2009, Dereka et al. 2010,
Santos et al. 2010), it can be deduced
that a clinically successful treatment
outcome may not predictably result in
reduction of the RANKL/OPG ratio.
It was of further interest to investigate
changes in RANKL and OPG levels
after treatment, in patients with G-
AgP. As it is debatable whether CP
and G-AgP constitute different diseases,
or different forms of the same disease
(Armitage & Cullinan 2010, Armitage
et al. 2010), it is anticipated that any
differential responses to periodontal
treatment could contribute to our under-
standing of this issue. It was found that
periodontal treatment did not alter sig-
nificantly RANKL and OPG GCF con-
centrations over a 3-month period.
Although at 4 months after treatment,
both RANKL and OPG levels were
significantly elevated, their relative
RANKL/OPG ratio maintained unchan-
ged throughout the whole monitoring
period. A potentially interesting finding
is the negative correlation between
RANKL or the RANKL/OPG ratio and
PBI, which may indicate that reduction
of inflammation is not necessarily asso-
ciated with a reduced capacity for bone
destruction in G-AgP. An interesting
finding is that when OPG levels were
compared between the two patient
groups, these were higher in CP com-
pared with G-AgP after 4 months of
treatment, which may indicate different
healing patterns. Hence, temporal differ-
ences may exist between CP and G-AgP
in the individual RANKL and OPG
responses after treatment, but the overall
common feature is that the relative
RANKL/OPG ratio is not affected in
either form of the disease, despite the
clinical improvements.
This finding does not devalue the
RANKL/OPG ratio as a potential diag-
nostic marker for periodontitis (Bostanci
et al. 2007), as it could still indicate sites
with prior disease occurrence at the
molecular level. However, the present
experimental design does not take under
consideration prior confirmed activity of
the sampled lesions. Studies using the
tolerance method (Haffajee et al. 1983)
to confirm periodontal disease progres-
sion, have indicated higher RANKL
GCF (Silva et al. 2008) and tissue
gene expression (Dutzan et al. 2009)
levels in active sites, compared with
inactive ones. In another study invol-
ving CP patients, it was reported that
sites with persistent bleeding on probing
after periodontal therapy exhibit higher
RANKL than OPG gingival tissue
expression (Menezes et al. 2008).
In conclusion, the present study indi-
cates that, despite its potential diagnos-
tic value, the RANKL/OPG ratio may
not be predictive of clinical improve-
ments of the periodontal status, as it
remains unchanged after conventional
periodontal treatment. A persistently
high RANKL/OPG ratio even after a
clinically successful treatment outcome
could indicate that tissue healing may
not be commensurate with the elimina-
tion of molecular mechanisms for bone
resorption, and thus a risk for further
periodontal tissue breakdown may still
exist. Nevertheless, such a question
would need to be addressed in long-
itudinal studies of prognostic nature,
with higher statistical power and poten-
tially taking under consideration prior
disease progression of the treated sites.
Moreover, the persistently high
RANKL/OPG ratio after initial perio-
dontal treatment may indicate the need
for adjunctive host response modulation
therapies for periodontal disease man-
agement (Salvi & Lang 2005). Such
therapies could target specifically the
RANKL–OPG system, thus preventing
or slowing down further bone loss. A
recently introduced pharmacological
intervention that serves in part this
purpose is the per os administration of
omega-3 fatty acids (El-Sharkawy et al.
2010). Alternatively, the effectiveness
of Demosunab, a novel monoclonal
antibody against RANKL used in the
treatment of bone-destructive disorders
(Rizzoli et al. 2010), needs to be tested
as an adjunctive treatment for perio-
dontitis as well.
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Clinical Relevance
Scientific rationale for study: RANKL
induces, whereas OPG inhibits bone
resorption. An increased RANKL/
OPG ratio in GCF is indicative of
the occurrence periodontitis. This
study investigated if this ratio is
predictably reduced in GCF after
non-surgical periodontal treatment.
Principal findings: The RANKL/
OPG ratio in GCF was not affected
by treatment, despite the improved
clinical outcomes over 4 months of
monitoring, in both CP and G-AgP.
Practical implications: The RANKL/
OPG ratio may not be a helpful
molecular predictor of clinically suc-
cessful treatment. As conventional
therapy does not negatively modulate
this ratio, the host could still be
susceptible to further bone loss.
Adjunctive treatments targeting
RANKL–OPG may be useful in this
respect.
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